CTRV Overview
Upcoming Projects (CTRV)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (CTRV)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CTRV)
-
ContraVir's (CTRV) Phase 2a Data Evaluating Tenofovir Exalidex (TXL) in Patients with Chronic Hepatitis B Virus (HBV) Infection
Ticker: CTRV
Occurred on: Apr 20, 2017 -
Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B expected to conclude in the fourth quarter of 2016
Ticker: CTRV
Occurred on: Oct 13, 2016 -
ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B
Ticker: CTRV
Occurred on: Jun 21, 2016 -
ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B
Ticker: CTRV
Occurred on: Jun 01, 2016 -
Final results from Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B expected in the fourth quarter of 2016
Ticker: CTRV
Occurred on: Jun 01, 2016
Strategic Initiatives (CTRV)
-
ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
Tickers: CTRV, Ciclofilin Pharmaceuticals
Announcement Date: May 31, 2016
